Funder
The study was initiated, funded, and sponsored by Novartis Pharmaceuticals Corporation.
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. International Agency for Research on Cancer (2012) GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012.
http://globocan.iarc.fr/Default.aspx
. Accessed 11 July 2017
2. Hosford SR, Miller TW (2014) Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenom Pers Med 7:203–215
3. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29
4. Miao H, Hartman M, Bhoo-Pathy N et al (2014) Predicting survival of de novo metastatic breast cancer in Asian women: systematic review and validation study. PLOS ONE 9:e93755
5. Cardoso F, Costa A, Senkus E et al (2017) 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 28:16–33
Cited by
86 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献